沙利卢马布在多关节性课程青少年异常性关节炎中:对2b期,开放标签,多中心研究的剂量发现和一年分析
Fabrizio De Benedetti1, Inmaculada C Penadés2, Irina Nikishina3
1Ospedale Pediatrico Bambino Gesù IRCCS, ERN-RITA Center, Rome, Italy.
Arthritis care & research
|November 14, 2025
概括
沙利卢马布有效治疗多关节性青少年异常性关节炎 (pcJIA),显示出疾病活性显著改善. 这种药物在儿科患者中表现出良好的安全性.
科学领域:
- 类风湿病学 类风湿病学
- 儿科风湿病学 儿科风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 青少年异常性关节炎 (JIA) 是一种慢性自身免疫性疾病,影响儿童.
- 多关节性JIA (pcJIA) 涉及多个关节,可能导致严重的残疾.
- 目前的治疗方法旨在减少炎症并防止关节损伤.
研究的目的:
- 评估沙利卢马布在患有PCJIA的儿科患者的安全性,疗效和药理动力学.
- 为了确定治疗pcJIA的沙利卢马布的最佳剂量.
- 为了比较pcJIA患者和成人类风湿性关节炎患者的沙利卢马布的药理动力学暴露.
主要方法:
- 一个2b期,开放标签,多部分研究 (NCT02776735) 涉及101名儿科患者.
- 剂量选择基于两个体重组的药理动力学,安全性和疗效.
- 主要终点:药物动力学暴露 (AUC,Cmax,C-trough). 二级终点:安全性和JIA-ACR响应率.
主要成果:
- 选择的剂量为3.0/4.0毫克/公斤每两周一次,适用于A/B体重组 (≥30-60公斤/≥10-<30公斤).
- 在第48周,接受选择剂量的患者的JIA-ACR 30/50/70/90应答率为100%/100%/93.8%/76.6%.
- 95.9%的患者经历了不良事件,其中37%报告3/4级中性质减退,但没有相关感染.
结论:
- 沙利卢马布在pcJIA患者的疾病活性中显示出临床相关的改善.
- 药物动力学暴露与200mg q2w剂量的成年类类风湿性关节炎患者相似.
- 在pcJIA中sarilumab的安全性概况与已知的数据一致.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
470
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
470
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
473
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
473
Bioavailability Study Design: Single Versus Multiple Dose Studies
189
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
189
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
420
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
420
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drugs for Treatment of Ulcerative Colitis in IBD
439
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
439


